Table 2 Clinical-biological characteristics
Age (mean years) | 70 (range 23–101) | N (%) |
|---|---|---|
Sex | Males | 53 (55%) |
Females | 43 (45%) | |
Histologic grade of the tumor | Low grade (Well-differentiated tumors and moderately differentiated tumors) | 86 (89.59%) |
High grade (Poorly differentiated tumors) | 3 (3.12%) | |
N/A | 7 (7.29%) | |
Stage at diagnosis | I | 7 (7.29%) |
II | 20 (20.83%) | |
III | 45 (46.88%) | |
IV | 21 (21.88%) | |
N/A | 3 (3.12%) | |
Tumour location | Sigmoid | 43 (44.79%) |
Right | 25 (26.04%) | |
Left | 7 (7.29%) | |
Transverse | 4 (4.17%) | |
Rectum | 10 (10.42%) | |
Splenic | 2 (2.08%) | |
N/A | 5 (5.21%) | |
Follow-up | 6 years ±7 months | |
Molecular Data | RAS mut | 6 (6.25%) |
Not RAS mut | 4 (4.17%) | |
N/A Ras mut | 86 (89.58%) | |
BRAFV600E | 3 (3.12%) | |
Not BRAFV600E | 8 (8.33%) | |
N/A BRAFV600E | 85 (88.54%) | |
Microsatellite instability (MSI) | 7 (7.29%) | |
Not Microsatellite instability (MSI) | 60 (62.50%) | |
N/A MSI | 29 (30.21%) |